Fluoropyrimidines are widely used in anti-cancer chemotherapy and are probably the drugs whose mechanism of activity is best understood (Heidelberger, 1975) . Essentially, two processes are involved in the cytotoxic activity of fluoropyrimidines. First, dTMP depletion may occur due to the inhibition of thymidilate synthetase by FdUMP. Second, fluoropyrimidine analogues can be incorporated into nascent RNA resulting in defective RNA species (Heidelberger, 1975) . The enzymatic processes converting FUra and FdUrd to the active nucleotide forms are summarised in Figure 1 . Briefly, FdUrd can be directly phosphorylated to FdUMP which inhibits thymidilate synthetase (Hartman & Heidelberger, 1961) . By another pathway FdUrd can be degraded to FUra by thymidine phosphorylase (Skold, 1960; Woodman et al., 1980) . Formation of 5-fluorouridine-5'-monophosphate (FUMP) can occur directly via a phosphoribosyl-transferase-mediated phosphoribosylation (Reyes, 1969) or a two step process involving uridine phosphorylase and uridine kinase (Skold, 1958) . Subsequent phosphorylation of FUMP leads to the formation of FUTP (Chauduri et al., 1958) , which can be incorporated into nascent RNA (Wilkinson & Pitot, 1973) . Alternatively, the intermediate 5-fluorouridine-5'-diphosphate (FUDP) can be degraded to 5-fluoro-2'-deoxyuridine-5'-diphosphate (FdUDP) by ribonucleotide reductase (Kent & Heidelberger, 1972) . Dephosphorylation of this FdUDP leads to the formation of FdUMP (Cohen et al., 1958) . Finally, FdUDP can be phosphorylated to 5-fluoro-2'-deoxyuridine-5'-triphosphate (FdUTP) which can be incorporated into nascent DNA (Kufe et al., 1981) .
Despite the extensive literature on this subject, less certainty exists with respect to which pathway is followed by the respective fluoropyrimidines or which target is decisive for cytotoxicity. The incorporation of FUra into RNA has been reported for a variety of animal and human cell lines (Glazer & Legraverend, 1980; Glazer & Hartman, 1979; Glazer & Peale, 1979; Major et al., 1982; Wilkinson & Pitot, 1973) and has been correlated with its cytotoxic effect (Kufe & Major, 1981) . For other cells, thymidylate synthetase has been reported to be the primary target for fluoropyrimidines, whilst the incorporation into nascent RNA was considered to be a second site effect (Ardalan et al., 1978; Spears et al., 1982) .
In this study, we describe a procedure to rapidly identify the target for the cytotoxic action fluoropyrimidines. Using The interference of fluoropyrimidines with thymidylate synthetase can be visualised by their effect on the incorporation of tritiated thymidine (dThd) into nascent DNA (Naaktgeboren et al., 1983) . In the absence of antimetabolites, DNA thymine will in part be unlabelled, derived from de novo synthesis, and in part labelled, derived from the exogenous pool of thymidine and incorporated via the salvage pathway. In case de novo thymidylate synthesis is blocked, all DNA thymine will be derived from the salvage pathway, hence resulting in an increase in the level of 13HjdThd incorporation. As confirmed in Figure 2 , both FdUrd and FUra were able to block thymidylate synthesis at concentrations of 10-6M and 10-4M, respectively. If thymidylate synthetase is the predominant target with respect to the action of these antimetabolites, rescue from fluoropyrimidine intoxication should be achieved upon addition of thymidine, in which case the blockade of thymidylate synthetase could be circumvented via the salvage pathway. A significant rescue was observed in case of FdUrd (Figure 3a) , whereas thymidine had no observable effect on the cytotoxicity of FUra (Figure 3b ), even at concen- 
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trations where complete rescue from FdUrd toxicity was achieved (Figure 4) Figure 5a . However, a different result was obtained for FUra ( Figure 5b ). Inhibition of cell proliferation was complete at concentrations of FUra at which no significant decrease in the level of 13HjdUrd incorporation could be observed. In order to confirm that the fluoropyrimidine-dependent inhibition of I3HIdUrd incorporation did occur at the level of thymidylate synthetase an identical experiment was performed using changes in the incorporation of tritiated thymidine as a measure of de novo thymidylate synthesis (cf. Figure 2) . As shown in Figure 6a , the increase in thymidine incorporation as a function of the FdUrd concentration coincided with the antiproliferative effect of FdUrd. However, in the case of FUra, the concentration required to achieve an increase in the incorporation of I3HIdThd was two logs above the concentration that sufficed for growth inhibition. 
Discussion
The results presented in this study justify the following conclusions with respect to the mode of action of fluoropyrimidines on L1210 leukaemia.
First, de novo thymidylate synthesis is the principal target for FdUrd activity. Following transmembrane transport FdUrd is phosphorylated to FdUMP, which in the presence of methylene tetrahydrofolic acid binds to thymidylate synthetase, resulting in the formation of an inactive ternary complex (Danenberg, 1977) . Second, no effective nucleoside phosphorylase mediated degradation of FdUrd to FUra occurs, as judged by the observation that complete rescue from FdUrd toxicity can be achieved upon addition of dThd and that inhibition of de novo thymidylate synthesis coincides perfectly with growth inhibition. Third, thymidylate synthetase inhibition is not involved in the action of FUra as judged by the observations thlat no rescue from FUra toxicity can be achieved upon addition of dThd and that growth inhibition ic complete at concentrations of FUra at which no inhibition of thymidylate synthesis can be observed. Fourth, conversion of FUra to FdUMP does occur, but this conversion does not contribute to the cytotoxic effect of FUra.
It should be noted that these observations have been made for L1210 leukaemia and are not necessarily valid for other cell lines. Different routes of metabolism of FUra have been reported (Laskin & Hakala, 1977; Mandel, 1981; Piper & Fox, 1982) , suggesting that the route of metabolism of fluoropyrimidines is an individual characteristic of tumours. The metabolic processing of fluoropyrimidines which precedes their cytotoxic action has been suggested to allow a simple prediction of the therapeutic efficacy of fluoropyrimidines (Ardalan et al., 1978 (Ardalan et al., , 1981 Kufe & Major, 1981) . However, the present study shows that FUra and FdUrd do not necessarily act on the same target. Therefore, studies on their route of metabolism seem unlikely to be sufficient in predicting cytotoxicity if the targets are not identified. In this context, the methodology described in this study may contribute to the development of reliable predictive assays for the efficacy of fluoropyrimidines.
